Japan’s advanced pharmaceutical industry is renowned, but until recently had relatively little involvement with the development of products to serve the developing world. The Global Health Innovative Technology Fund (GHIT) is aiming to change that. A public-private partnership fund, GHIT invests in the development of drugs, diagnostics and vaccines for malaria, TB, HIV/AIDS and neglected tropical diseases. Camilla Burkot recently sat down with GHIT’s CEO, Dr BT Slingsby, to discuss the fund’s origins, the kinds of partnerships and products it is fostering, and the impact that these can be expected to have in the coming years.
Read and subscribe to our daily blogs at devpolicy.org.
Learn more about our research and join our public events at devpolicy.anu.edu.au.
Follow us on Twitter, Facebook, LinkedIn and Instagram for latest updates on our blogs, research and events.
You can send us feedback, and ideas for episodes too, to devpolicy@anu.edu.au.
